The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenues | 192,103 | - |
| Cost of goods sold | 18,965 | - |
| Selling expenses | 58,386 | - |
| Marketing expenses | 18,672 | - |
| General and administrative expenses | 31,746 | - |
| Acquisition-related expenses | 70,874 | - |
| ONAPGO | 352 | - |
| SPN820 | 1,111 | - |
| SPN817 | 4,872 | - |
| Qelbree | 3,168 | - |
| ZURZUVAE | 1,385 | - |
| Early Stage Program And Other | 5,173 | - |
| Total external development program expenses | 16,061 | - |
| Internal employee-related expenses | 13,305 | - |
| Total research and development expenses | 29,366 | - |
| Other segment items | 9,211 | - |
| Net earnings (loss) | -45,117 | 10,672 |
| Depreciation and amortization | 24,806 | 41,741 |
| Amortization of premium/discount on marketable securities | 921 | 1,106 |
| Change in fair value of contingent consideration | 0 | 7,660 |
| Realized gains from sales of marketable securities | 0 | - |
| Share-based compensation expense | 7,825 | 15,575 |
| Deferred income tax benefit | -2,645 | -11,152 |
| Inventory valuation write-down | -239 | 1,467 |
| Payment of contingent consideration | 0 | -4,900 |
| Other noncash adjustments, net | -3,827 | -3,779 |
| Accounts receivable | 7,131 | -1,246 |
| Inventories | 12,940 | -9,618 |
| Prepaid expenses and other assets | 11,144 | -4,870 |
| Accrued product returns and rebates | 3,543 | 12,211 |
| Accounts payable and other liabilities | -21,528 | -2,547 |
| Net cash provided by operating activities | -61,664 | 89,134 |
| Purchases of marketable securities | 126,628 | 259,113 |
| Maturities of marketable securities | 468,556 | 266,605 |
| Acquisition of sage, net of cash acquired | 293,093 | - |
| Purchases of property and equipment | 129 | 782 |
| Net cash provided by (used in) investing activities | 48,706 | 6,710 |
| Proceeds from issuance of common stock | 23,741 | 5,318 |
| Employee taxes paid related to net share settlement of equity awards | 811 | 3,387 |
| Payment of contingent consideration | 1,862 | 22,395 |
| Net cash provided by financing activities | 21,068 | -20,464 |
| Net change in cash, cash equivalents, and restricted cash | 8,110 | 75,380 |
| Cash and cash equivalents at beginning of period | 69,331 | - |
| Cash and cash equivalents at end of period | 152,821 | - |
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)